On Feb. 24, 2021, NeuroRx, announced that the phase 2b/3 trial of ZYESAMI for the treatment of Respiratory Failure in critically ill patients with COVID-19 had demonstrated multidimensional benefit around its pre-specified primary endpoint.

Although not envisioned at the start of the clinical trial, High Flow Nasal Oxygen had become the predominant form of treatment in Covid-19 respiratory failure, with mechanical ventilation reserved for those whose blood oxygen levels cannot be maintained on this less invasive modality. The trial was conducted at 10 U.S. hospitals under the direction of NeuroRx in collaboration with RELIEF THERAPEUTICS.